Close

Leap Therapeutics Announces Encouraging Data from TRX518 Phase 1 in Immunosuppressive Cell Reduction (MCUR)

Go back to Leap Therapeutics Announces Encouraging Data from TRX518 Phase 1 in Immunosuppressive Cell Reduction (MCUR)

Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist

November 12, 2016 2:00 PM EST

Data Presented During the Presidential Session at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Leap Therapeutics, Inc. today announced the presentation of data from its Phase 1 clinical trial of TRX518 in patients with advanced relapsed or refractory solid tumors. Roberta Zappasodi, Ph.D., Parker Institute Scholar and Research Scholar in the Ludwig Collaborative Laboratory at Memorial Sloan Kettering Cancer Center, a site participating in the Phase 1 study, led an oral presentation during the Presidential Session entitled Analysis of pharmacodynamic biomarkers in the first-in-human... More